Why France belongs on a Thai supplier's map

France ran a multi-year therapeutic-use experiment for medical cannabis and is now moving toward a generalised framework, with the enabling regulatory texts expected to land through 2026. That transition reshapes supply-side planning. An experiment gates access tightly and by cohort. A generalised regime opens a standing, prescription-driven market with a licensed importer and distributor base to serve it.

For a licensed Thai cultivation farm that has read our companion briefs on Germany's BfArM pathway and the Swiss Swissmedic framework, the French shape is familiar. One national regulator sits at the centre, and internationally cultivated flower routes through French-licensed importers rather than direct cultivator-to-pharmacy.

This brief outlines the framework at a general level, the documentation a French importer expects on the cultivator side, and how CannaBless — an export brokerage, not an exporter — connects licensed Thai supply into it. It carries no medical, dosing, or patient guidance. The framing is B2B regulated-supply throughout.

ANSM and the shift from experiment to generalised framework

Medical cannabis in France is overseen by the Agence nationale de sécurité du médicament et des produits de santé (ANSM), the national medicines regulator. Under the generalised regime taking shape, ANSM's remit spans product assessment, the registration of eligible cannabis-based medicines, and prescription oversight on defined review timelines.

Cannabis remains a controlled substance. Movement of product across the French border therefore also engages narcotics-handling permissions aligned with the International Narcotics Control Board reporting framework that governs cross-border narcotics worldwide.

The practical division of labour is the one that recurs across every market we cover. The licensed French importer or distributor holds the domestic authorisations, manages the narcotics permissions, and carries the French regulatory burden. The Thai cultivation farm does not hold French licences and does not need to. It supplies clean, documentation-complete material into a party that already carries the French compliance stack.

What a French importer verifies before sourcing

French importers expect imported medical cannabis to be produced under Good Manufacturing Practice conditions recognised for the market, so the cultivator-side diligence mirrors the German and Swiss pathways closely. In practice, the pack a French importer asks for includes:

GACP cultivation certification from the country of origin — TH-GACP for Thailand, demonstrating compliance with the national Good Agricultural and Collection Practices standard
Per-batch Certificate of Analysis from an ISO/IEC 17025-accredited laboratory: full cannabinoid profile, terpene panel, microbial limits, pesticide residues, heavy metals, and mycotoxins, each tied to a batch identifier
Certificate of Origin and Phytosanitary Certificate from the Thai plant-health authority
Post-harvest manufacture evidence at a GMP-equivalent standard covering drying, curing, and packaging
Country-of-origin export licence specific to the shipment, citing the French importer's authorisation
Cold-chain shipping documentation with continuous temperature and humidity logging from harvest through to the French port of entry

A Certificate of Analysis that reports cannabinoids without a quantified per-terpene breakdown meets the same scepticism in France that it draws in Germany. The documentation is what earns the conversation.

Where the Thai supply side sits

The Thai export side rests on the six DTAM export-eligible categories: hospitals under the Sanatorium Act; herbal-product manufacturing or sales licence holders; drug manufacturing or sales licence holders; Category-5 narcotics (cannabis and hemp extract) licence holders; certified traditional healers; and cultivation sites supplying licensed buyers. Most farms CannaBless represents hold the sixth status and sell into a licensed downstream party.

The Thai supply universe is narrower than headline farm counts suggest. Roughly 79 GACP-certified operators sat on the DTAM register as of 16 July 2025 — a scarcity that makes selectivity, not volume, the constraint on the cultivator side. The framework, and what a foreign importer should verify, is covered in full in our brief on what changed for Thai export in 2026.

One point worth stating plainly for any investor reading this. Foreign participation in a Thai cultivation operation is a matter of lawful joint-venture or BOI-promoted investment structuring, never nominee arrangements. Nominee shareholding is a criminal offence under the Thai Foreign Business Act §36 and exposes the parties to penalties and a court-ordered unwinding. The supply side of a French deal is built on farms whose licence and ownership positions withstand exactly that scrutiny.

How CannaBless approaches French supply conversations

CannaBless is a Thailand-based, cultivator-side export brokerage. We register and document the licensed Thai farms we represent, facilitate their export-licensing documentation, and connect them to licensed French importers and distributors operating under the ANSM framework. We do not hold French licences, and we do not intend to — that is the importer's domain. We do not sell to French physicians, pharmacies, or patients.

Our role is to present GACP-certified, ISO/IEC 17025-tested, cold-chain-documented Thai flower with a complete documentation pack, so a French importer can clear its side cleanly. The shipment under Italian import permit IT-20261155773424 — 700 kg of Cannabis Sativa L., phytosanitary-certified and GACP-aligned, arriving Genova in June 2026 — is the live proof anchor. It demonstrates that the cultivator side of this exact documentation pattern already operates. A French conversation begins from the same base.

Talk to the export desk

If you are a French-licensed medical cannabis importer or distributor evaluating Thai-origin supply, the export desk responds within one business day from Bangkok (UTC+7). We share licence-stack references, DTAM training records, and TH-GACP certification without asking for a letter of intent first. The documentation is what earns the conversation, so we would rather you have it in hand.